Symbols / CELU Stock $0.77 +12.36% Celularity Inc.

Healthcare • Biotechnology • United States • NCM
CELU (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Robert Joseph Hariri M.D., Ph.D.
Exch · Country NCM · United States
Market Cap 22.39M
Enterprise Value 88.77M
Income -91.80M
Sales 26.55M
FCF (ttm) 5.38M
Book/sh -1.32
Cash/sh 0.21
Employees 115
Insider 10d —
IPO Aug 08, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.36
PEG —
P/S 0.84
P/B -0.59
P/C —
EV/EBITDA -1.64
EV/Sales 3.34
Quick Ratio 0.14
Current Ratio 0.15
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -3.59
EPS next Y -0.57
EPS Growth —
Revenue Growth -77.40%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-08-18
Earnings (prior) 2025-08-18
ROA -30.93%
ROE —
ROIC —
Gross Margin 24.39%
Oper. Margin -4.92%
Profit Margin 0.00%
Shs Outstand 28.95M
Shs Float 18.87M
Insider Own 37.18%
Instit Own 12.77%
Short Float 5.18%
Short Ratio 1.63
Short Interest 345.34K
52W High 4.35
vs 52W High -82.22%
52W Low 0.69
vs 52W Low 12.12%
Beta 0.48
Impl. Vol. 14.63%
Rel Volume 0.60
Avg Volume 116.38K
Volume 70.09K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.69
Price $0.77
Change 12.36%
About

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.77
Latest analyst target
3. DCF / Fair value
$3.35
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.77
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-09-09 up WBB Securities Hold → Buy $6
2025-08-18 init WBB Securities — → Speculative Buy $6
News
RSS: Latest CELU news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-13 BRIGIDO STEPHEN Officer — 821 — —
2026-04-13 HARIRI ROBERT J Chief Executive Officer — 3,281 — —
2026-04-13 HAINES JOHN R. Officer — 1,641 — —
2026-01-12 PARKS DIANE L. Director — 30,000 $0.00 $0
2026-01-12 DIAMANDIS PETER Director — 20,385 $0.00 $0
2026-01-12 LING GEOFFREY M. D. Director — 19,231 $0.00 $0
2026-01-12 LEVIEN VINCENT Director — 28,847 $0.00 $0
2025-12-29 PARKS DIANE L. Director — 125,000 $0.00 $0
2025-12-29 DIAMANDIS PETER Director — 125,000 $0.00 $0
2025-12-29 LING GEOFFREY M. D. Director — 125,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
26.55
-51.03%
54.22
+138.11%
22.77
+26.68%
17.98
Operating Revenue
26.55
-51.03%
54.22
+138.11%
22.77
+26.68%
17.98
Cost Of Revenue
20.07
+33.92%
14.99
-6.41%
16.02
-18.56%
19.66
Reconciled Cost Of Revenue
14.27
+61.81%
8.82
-0.73%
8.88
-28.47%
12.42
Gross Profit
6.48
-83.49%
39.23
+480.77%
6.75
+499.70%
-1.69
Operating Expense
67.78
-12.85%
77.78
-6.55%
83.23
-43.21%
146.58
Research And Development
15.03
-13.58%
17.39
-42.93%
30.46
-61.12%
78.36
Selling General And Administration
51.27
-12.58%
58.64
+15.95%
50.58
-23.39%
66.02
Total Expenses
87.86
-5.30%
92.77
-6.53%
99.25
-40.30%
166.24
Operating Income
-61.31
-59.03%
-38.55
+49.59%
-76.48
+48.42%
-148.27
Total Operating Income As Reported
-61.31
-59.83%
-38.36
+80.05%
-192.29
-651.12%
-25.60
EBITDA
-77.66
-77.70%
-43.71
+76.24%
-183.95
-878.08%
23.64
Normalized EBITDA
-65.17
-61.34%
-40.39
+45.64%
-74.30
+47.35%
-141.13
Reconciled Depreciation
7.29
-7.91%
7.92
-15.04%
9.32
-1.19%
9.44
EBIT
-84.96
-64.56%
-51.63
+73.29%
-193.27
-1460.58%
14.21
Total Unusual Items
-12.50
-276.82%
-3.32
+96.97%
-109.64
-166.54%
164.78
Total Unusual Items Excluding Goodwill
-12.50
-276.82%
-3.32
+96.97%
-109.64
-166.54%
164.78
Special Income Charges
-9.25
-148.88%
-3.71
+96.79%
-115.81
-194.41%
122.67
Other Special Charges
6.36
+62.64%
3.91
—
—
Impairment Of Capital Assets
—
0.00
-100.00%
112.35
+3012.11%
3.61
Restructuring And Mergern Acquisition
0.00
+100.00%
-0.19
+99.82%
-104.34
+17.37%
-126.28
Write Off
2.89
0.00
-100.00%
107.80
0.00
Net Income
-91.72
-58.43%
-57.89
+70.51%
-196.29
-1483.14%
14.19
Pretax Income
-91.71
-58.42%
-57.89
+70.51%
-196.28
-1481.80%
14.21
Net Non Operating Interest Income Expense
-6.49
-9.42%
-5.93
-120.15%
-2.69
-838.36%
0.36
Interest Expense Non Operating
6.75
+7.82%
6.26
+107.76%
3.02
0.00
Net Interest Income
-6.49
-9.42%
-5.93
-120.15%
-2.69
-838.36%
0.36
Interest Expense
6.75
+7.82%
6.26
+107.76%
3.02
0.00
Interest Income Non Operating
0.26
-20.85%
0.33
+3.44%
0.32
-12.33%
0.36
Interest Income
0.26
-20.85%
0.33
+3.44%
0.32
-12.33%
0.36
Other Income Expense
-23.91
-78.35%
-13.41
+88.55%
-117.11
-172.24%
162.11
Other Non Operating Income Expenses
-11.41
-13.11%
-10.09
-35.14%
-7.47
-179.77%
-2.67
Gain On Sale Of Security
-3.25
-917.34%
0.40
-93.54%
6.16
-85.36%
42.11
Gain On Sale Of Business
—
—
—
—
Tax Provision
0.00
0.00
-100.00%
0.01
-23.08%
0.01
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
-2.62
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-91.72
-58.43%
-57.89
+70.51%
-196.29
-1483.14%
14.19
Net Income From Continuing Operation Net Minority Interest
-91.72
-58.43%
-57.89
+70.51%
-196.29
-1483.14%
14.19
Net Income From Continuing And Discontinued Operation
-91.72
-58.43%
-57.89
+70.51%
-196.29
-1483.14%
14.19
Net Income Continuous Operations
-91.72
-58.43%
-57.89
+70.51%
-196.29
-1483.14%
14.19
Normalized Income
-81.84
-49.96%
-54.58
+37.02%
-86.65
+42.46%
-150.58
Net Income Common Stockholders
-91.80
-58.57%
-57.89
+70.51%
-196.29
-1483.14%
14.19
Otherunder Preferred Stock Dividend
0.06
0.00
—
—
Diluted EPS
—
-2.64
+76.04%
-11.02
-1260.00%
0.95
Basic EPS
—
-2.64
+76.04%
-11.02
-1191.09%
1.01
Basic Average Shares
—
21.89
+22.89%
17.81
+27.32%
13.99
Diluted Average Shares
—
21.89
+22.89%
17.81
+18.89%
14.98
Diluted NI Availto Com Stockholders
-91.80
-58.57%
-57.89
+70.51%
-196.29
-1483.14%
14.19
Amortization
1.49
-14.83%
1.75
-20.06%
2.19
+0.00%
2.19
Amortization Of Intangibles Income Statement
1.49
-14.83%
1.75
-20.06%
2.19
+0.00%
2.19
Depreciation Amortization Depletion Income Statement
1.49
-14.83%
1.75
-20.06%
2.19
+0.00%
2.19
Depreciation And Amortization In Income Statement
1.49
-14.83%
1.75
-20.06%
2.19
+0.00%
2.19
Preferred Stock Dividends
0.02
—
—
—
Line Item Trend 2023-12-31
Total Assets
143.89
Current Assets
19.79
Cash Cash Equivalents And Short Term Investments
0.23
Cash And Cash Equivalents
0.23
Receivables
12.12
Accounts Receivable
10.05
Gross Accounts Receivable
15.88
Allowance For Doubtful Accounts Receivable
-5.84
Inventory
5.75
Prepaid Assets
1.37
Other Current Assets
0.33
Total Non Current Assets
124.10
Net PPE
78.82
Gross PPE
106.10
Accumulated Depreciation
-27.28
Properties
0.00
Buildings And Improvements
—
Machinery Furniture Equipment
7.78
Construction In Progress
0.02
Other Properties
25.08
Leases
73.21
Goodwill And Other Intangible Assets
18.35
Goodwill
7.35
Other Intangible Assets
11.00
Other Non Current Assets
26.93
Total Liabilities Net Minority Interest
102.93
Current Liabilities
67.30
Payables And Accrued Expenses
22.78
Payables
14.14
Accounts Payable
14.14
Current Accrued Expenses
8.63
Current Debt And Capital Lease Obligation
39.24
Current Debt
39.24
Other Current Borrowings
39.24
Current Capital Lease Obligation
—
Current Deferred Liabilities
2.83
Current Deferred Revenue
2.83
Other Current Liabilities
2.45
Total Non Current Liabilities Net Minority Interest
35.63
Long Term Debt And Capital Lease Obligation
26.18
Long Term Debt
—
Long Term Capital Lease Obligation
26.18
Non Current Deferred Liabilities
3.19
Non Current Deferred Revenue
3.19
Non Current Deferred Taxes Liabilities
0.01
Other Non Current Liabilities
1.90
Preferred Securities Outside Stock Equity
—
Stockholders Equity
40.96
Common Stock Equity
40.96
Capital Stock
0.02
Common Stock
0.02
Preferred Stock
0.00
Share Issued
19.38
Ordinary Shares Number
19.38
Treasury Shares Number
0.00
Additional Paid In Capital
882.73
Retained Earnings
-841.79
Gains Losses Not Affecting Retained Earnings
0.00
Treasury Stock
—
Other Equity Adjustments
—
Total Equity Gross Minority Interest
40.96
Total Capitalization
40.96
Working Capital
-47.51
Invested Capital
80.20
Total Debt
65.42
Net Debt
39.01
Capital Lease Obligations
26.18
Net Tangible Assets
22.61
Tangible Book Value
22.61
Current Notes Payable
—
Derivative Product Liabilities
4.36
Interest Payable
0.00
Notes Receivable
2.07
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-13.25
-107.06%
-6.40
+83.45%
-38.69
+71.94%
-137.88
Cash Flow From Continuing Operating Activities
-13.26
-107.11%
-6.40
+83.45%
-38.69
+71.94%
-137.88
Net Income From Continuing Operations
-91.72
-58.43%
-57.89
+70.51%
-196.29
-1483.14%
14.19
Depreciation Amortization Depletion
7.29
-7.91%
7.92
-15.04%
9.32
-1.19%
9.44
Depreciation
5.80
-5.93%
6.17
-13.49%
7.13
—
Amortization Cash Flow
1.49
-14.89%
1.75
-20.06%
2.19
—
Depreciation And Amortization
7.29
-7.91%
7.92
-15.04%
9.32
-1.19%
9.44
Amortization Of Intangibles
1.49
-14.89%
1.75
-20.06%
2.19
—
Other Non Cash Items
9.11
+64.06%
5.55
+106.02%
-92.31
+25.35%
-123.67
Stock Based Compensation
10.38
-10.29%
11.57
-22.96%
15.02
-5.29%
15.86
Provisionand Write Offof Assets
1.25
+361.62%
0.27
-89.42%
2.56
+36.44%
1.88
Asset Impairment Charge
7.22
+1450.43%
0.47
-99.79%
225.53
+4896.26%
4.51
Deferred Tax
—
—
0.00
+100.00%
-0.00
Deferred Income Tax
—
—
0.00
+100.00%
-0.00
Operating Gains Losses
9.61
+173.76%
3.51
+160.93%
-5.76
+86.32%
-42.11
Gain Loss On Investment Securities
3.25
+917.34%
-0.40
+93.09%
-5.76
+86.32%
-42.11
Change In Working Capital
33.59
+51.32%
22.20
+582.66%
3.25
+118.09%
-17.98
Change In Receivables
7.55
+290.30%
-3.97
+41.88%
-6.83
-90.49%
-3.58
Changes In Account Receivables
7.55
+290.30%
-3.97
+41.88%
-6.83
-90.49%
-3.58
Change In Inventory
10.25
+63.05%
6.28
+826.47%
-0.86
+94.88%
-16.89
Change In Prepaid Assets
-0.04
-104.42%
0.91
-83.86%
5.61
+11340.82%
0.05
Change In Payables And Accrued Expense
16.58
-9.77%
18.37
+419.75%
3.54
+100.62%
1.76
Change In Accrued Expense
13.45
+47.27%
9.13
+284.08%
-4.96
-205.35%
4.71
Change In Payable
3.13
-66.17%
9.24
+8.73%
8.50
+388.23%
-2.95
Change In Account Payable
3.13
-66.17%
9.24
+8.73%
8.50
+388.23%
-2.95
Change In Other Working Capital
-0.74
-222.28%
0.61
-66.39%
1.80
+162.06%
0.69
Investing Cash Flow
0.00
-100.00%
0.51
+112.70%
-4.05
+22.69%
-5.24
Cash Flow From Continuing Investing Activities
0.00
-100.00%
0.51
+112.70%
-4.05
+22.69%
-5.24
Capital Expenditure
—
-0.16
+96.02%
-4.05
+22.69%
-5.24
Capital Expenditure Reported
0.00
+100.00%
-0.16
+84.64%
-1.05
+79.98%
-5.24
Net Business Purchase And Sale
0.00
+100.00%
-1.50
0.00
—
Purchase Of Business
0.00
+100.00%
-1.50
0.00
—
Gain Loss On Sale Of Business
—
—
—
—
Net Intangibles Purchase And Sale
—
0.00
+100.00%
-3.00
0.00
Purchase Of Intangibles
—
0.00
+100.00%
-3.00
0.00
Net Other Investing Changes
—
2.17
—
—
Financing Cash Flow
18.65
+178.30%
6.70
-72.19%
24.09
-79.89%
119.84
Cash Flow From Continuing Financing Activities
18.65
+178.30%
6.70
-72.19%
24.09
-79.89%
119.84
Net Issuance Payments Of Debt
-0.12
+99.13%
-13.90
+6.16%
-14.81
-117.28%
85.69
Issuance Of Debt
0.00
-100.00%
3.62
+81.10%
2.00
-97.67%
85.69
Repayment Of Debt
-0.12
+99.31%
-17.52
-4.22%
-16.81
0.00
Long Term Debt Issuance
—
—
17.37
-62.64%
46.49
Net Long Term Debt Issuance
—
—
17.37
-62.64%
46.49
Short Term Debt Issuance
0.00
-100.00%
3.62
+81.10%
2.00
-94.90%
39.20
Short Term Debt Payments
-0.12
+99.31%
-17.52
-4.22%
-16.81
0.00
Net Short Term Debt Issuance
-0.12
+99.13%
-13.90
+6.16%
-14.81
-137.78%
39.20
Net Common Stock Issuance
4.00
-33.33%
6.00
-72.59%
21.89
-40.07%
36.52
Common Stock Payments
—
—
—
—
Cash Dividends Paid
-5.90
0.00
—
—
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
20.41
+35.58%
15.06
-19.36%
18.67
+2066.24%
0.86
Net Other Financing Charges
0.26
+155.56%
-0.46
+72.25%
-1.65
+48.86%
-3.23
Changes In Cash
5.39
+562.78%
0.81
+104.37%
-18.64
+19.91%
-23.27
Beginning Cash Position
10.98
+8.01%
10.16
-64.71%
28.80
-44.69%
52.08
End Cash Position
16.37
+49.15%
10.98
+8.01%
10.16
-64.71%
28.80
Free Cash Flow
-13.25
-101.98%
-6.56
+84.64%
-42.73
+70.14%
-143.11
Interest Paid Supplemental Data
2.50
+1637.50%
0.14
-86.58%
1.07
0.00
Income Tax Paid Supplemental Data
0.05
0.00
—
0.00
Common Stock Issuance
4.00
-33.33%
6.00
-72.59%
21.89
-40.07%
36.52
Issuance Of Capital Stock
4.00
-33.33%
6.00
-72.59%
21.89
-40.07%
36.52
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
Sale Of Business
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category